File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

TitleNeratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
Authors
Issue Date2020
Citation
J Clin Oncol, 2020, v. 38, p. 3138-49 How to Cite?
Persistent Identifierhttp://hdl.handle.net/10722/289768

 

DC FieldValueLanguage
dc.contributor.authorSaura, C-
dc.contributor.authorOliveira, M-
dc.contributor.authorFeng, YH-
dc.contributor.authorDai, MS-
dc.contributor.authorChen, SW-
dc.contributor.authorHurvitz, SA-
dc.contributor.authorKim, SB-
dc.contributor.authorMoy, B-
dc.contributor.authorDelaloge, S-
dc.contributor.authorGradishar, W-
dc.contributor.authorMasuda, N-
dc.contributor.authorPalacova, M-
dc.contributor.authorTrudeau, ME-
dc.contributor.authorMattson, J-
dc.contributor.authorYap, YS-
dc.contributor.authorV, MF-
dc.contributor.authorDe Laurentiis, M-
dc.contributor.authorYeh, YM-
dc.contributor.authorChang, HT-
dc.contributor.authorYau, TCC-
dc.contributor.authorWildiers, H-
dc.contributor.authorHaley, B-
dc.contributor.authorFagnani, D-
dc.contributor.authorLu, YS-
dc.contributor.authorCrown, J-
dc.contributor.authorLin, J-
dc.contributor.authorTakahashi, M-
dc.contributor.authorTakano, T-
dc.contributor.authorYamaguchi, M-
dc.contributor.authorFujii, T-
dc.contributor.authorYao, B-
dc.contributor.authorBebchuk, J-
dc.contributor.authorKeyvanjah, K-
dc.contributor.authorBryce, R-
dc.contributor.authorBrufsky, A-
dc.contributor.authorNALA Investigators, -
dc.date.accessioned2020-10-22T08:17:12Z-
dc.date.available2020-10-22T08:17:12Z-
dc.date.issued2020-
dc.identifier.citationJ Clin Oncol, 2020, v. 38, p. 3138-49-
dc.identifier.urihttp://hdl.handle.net/10722/289768-
dc.languageeng-
dc.relation.ispartofJ Clin Oncol-
dc.titleNeratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial-
dc.typeArticle-
dc.identifier.emailYau, TCC: tyaucc@hku.hk-
dc.identifier.authorityYau, TCC=rp01466-
dc.identifier.doi10.1200/JCO.20.00147-
dc.identifier.scopuseid_2-s2.0-85088803559-
dc.identifier.hkuros316106-
dc.identifier.volume38-
dc.identifier.spage3138-
dc.identifier.epage49-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats